Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia

Maslak, P.G.; Weiss, M.A.; Berman, E.; Yao, T.J.; Tyson, D.; Golde, D.W.; Scheinberg, D.A.

Leukemia 10(1): 32-39

1996


ISSN/ISBN: 0887-6924
PMID: 8558934
Document Number: 1007
Given the high treatment-related mortality in elderly patients with acute myelogenous leukemia (AML), we undertook a study using granulocyte colony-stimulating factor (G-CSF) following chemotherapy in an effort to ameliorate toxicity. Patients ( gt 60 years) received induction with idarubicin 12 mg/m-2/day times 3 and cytosine arabinoside (Ara-C) 200 mg/m-2/day times 5. A second course of chemotherapy consisting of mitoxantrone 12 mg/m-2/day times 3, etoposide (VP-16) 150 mg/m-2/day times 3 and Ara-C 200 mg/m-2/day times 4 was given approximately 1 month after achieving a complete remission (CR) or immediately if patients failed the first induction. Twenty-four hours following completion of the chemotherapy, G-CSF (10 mu-g/kg/day continuous i.v. infusion) was started. A historical control group of 28 patients treated without G-CSF was used for comparison. Twenty-six patients were evaluable for response. Following induction, the recovery of neutrophils to greater than 500/mu-l and 1000/mu-l was more rapid in the responders who received G-CSF compared to historical controls (median 13 vs 17 days, P = 0.008; 14 vs 19 days, P = 0.005). The toxic death rate of 8% in the study group was significantly lower than the 32% mortality observed in the historical controls (P = 0.04). There was no difference in supportive care requirements or infectious complications. The complete remission (CR) rate was 58% in the entire study group with 71% of de novo AML patients achieving CR. Disease-free survival and overall survival were comparable between the study and historical control groups. These results indicate that G-CSF benefits elderly patients after intensive chemotherapy for AML by decreasing the duration of neutropenia. The reduced neutropenic period may have contributed to the small number of early toxic deaths.

Document emailed within 1 workday
Secure & encrypted payments

Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia